EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Pretax loss widens to £1.7 million in the six months to September 30 from £1.3 million a year prior. Revenue falls to £17.8 million from £20.1 million, administrative expenses increase to £1.7 million from £1.3 million.

‘As we pass our second anniversary as a listed company, we are entering into a new phase that combines a portfolio contributing near and mid-term revenues commencing in 2025, with an expanded pipeline of global product development opportunities. However, the market for digital diagnostic products is in its infancy and the pace of change is rapid, therefore accurately forecasting revenue growth in detail is challenging at this time. The directors expect to provide further updates in this regard in the first quarter of 2025, but we are confident that 2025 is a year of considerable potential for EDX Medical,’ company says.

Current share price: 8.00 pence

Copyright 2024 Alliance News Ltd. All Rights Reserved.